Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience
Abstract Background Bicyclol, the most commonly-used liver hepatoprotective drug in China, is often selected to control disease progression in CHB patients who refuse anti-viral treatment. However, data on histological changes after bicyclol treatment in these patients are scarce. Therefore, this st...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-06-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12876-019-1005-1 |
| _version_ | 1818969602620653568 |
|---|---|
| author | Xiaoling Chi Huanming Xiao Meijie Shi Gaoshu Cai Yubao Xie Junmin Jiang Guangjun Tian Shuduo Wu Chaozhen Zhang Pengtao Zhao Jiezhen Chen |
| author_facet | Xiaoling Chi Huanming Xiao Meijie Shi Gaoshu Cai Yubao Xie Junmin Jiang Guangjun Tian Shuduo Wu Chaozhen Zhang Pengtao Zhao Jiezhen Chen |
| author_sort | Xiaoling Chi |
| collection | DOAJ |
| description | Abstract Background Bicyclol, the most commonly-used liver hepatoprotective drug in China, is often selected to control disease progression in CHB patients who refuse anti-viral treatment. However, data on histological changes after bicyclol treatment in these patients are scarce. Therefore, this study has been conducted to find out whether bicyclol has good benefits of histological improvement in CHB patients who refuse anti-viral agents. Methods The demographic, clinical and pathological data were collected from CHB patients who received bicyclol from January 2010 to June 2016. Improvement in liver inflammation or fibrosis is defined as at least one-grade or one-stage decrease as measured by the Scheuer scoring system. Thirty patients treated with ETV for 48 weeks were chosen as a control group to compare the histological improvement between bicyclol and entecavir (ETV) after 48-week treatment. Results A total of 123 patients with CHB treated with bicyclol were included in this study. Paired liver biopsies were performed in 70 patients. Inter-biopsy interval was 17.44 ± 8.90 months (12–60 months). As shown by facts, 41.4% patients achieved liver inflammation improvement, while only 10.0% patients showed liver inflammation progression after bicyclol treatment. In regarding to liver fibrosis, as shown by facts, 28.6% patients achieved fibrosis improvement. More importantly, It was found that the proportions of patients with liver inflammation and fibrosis improvement were both not significantly lower than those in ETV group (53.3% vs 63.3 and 36.7% vs 43.4%). Most of patients (82.4%) with elevated baseline ALT became normal after bicyclol treatment. More importantly, as shown by the multi-variate analysis, the treatment course of bicyclol was an independent factor for liver inflammation improvement. With the HBeAg status adjusted, ALT and HBV-DNA quantity, the odds ratio (95% confidence interval) of patients with ≥48-week treatment was 5.756 (1.893,17.500) when compared with patients via < 48-week treatment. Conclusion Bicyclol can improve liver inflammation and the ALT normalization rate of CHB patients, especially when the treatment course is prolonged. This has confirmed that bicyclol could control hepatitis activity, which might be a good choice for CHB patients who refuse anti-viral treatments. |
| first_indexed | 2024-12-20T14:23:12Z |
| format | Article |
| id | doaj.art-380a77df56b640d793dd309b58762bd7 |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-12-20T14:23:12Z |
| publishDate | 2019-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-380a77df56b640d793dd309b58762bd72022-12-21T19:37:52ZengBMCBMC Gastroenterology1471-230X2019-06-011911810.1186/s12876-019-1005-1Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experienceXiaoling Chi0Huanming Xiao1Meijie Shi2Gaoshu Cai3Yubao Xie4Junmin Jiang5Guangjun Tian6Shuduo Wu7Chaozhen Zhang8Pengtao Zhao9Jiezhen Chen10Department of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineAbstract Background Bicyclol, the most commonly-used liver hepatoprotective drug in China, is often selected to control disease progression in CHB patients who refuse anti-viral treatment. However, data on histological changes after bicyclol treatment in these patients are scarce. Therefore, this study has been conducted to find out whether bicyclol has good benefits of histological improvement in CHB patients who refuse anti-viral agents. Methods The demographic, clinical and pathological data were collected from CHB patients who received bicyclol from January 2010 to June 2016. Improvement in liver inflammation or fibrosis is defined as at least one-grade or one-stage decrease as measured by the Scheuer scoring system. Thirty patients treated with ETV for 48 weeks were chosen as a control group to compare the histological improvement between bicyclol and entecavir (ETV) after 48-week treatment. Results A total of 123 patients with CHB treated with bicyclol were included in this study. Paired liver biopsies were performed in 70 patients. Inter-biopsy interval was 17.44 ± 8.90 months (12–60 months). As shown by facts, 41.4% patients achieved liver inflammation improvement, while only 10.0% patients showed liver inflammation progression after bicyclol treatment. In regarding to liver fibrosis, as shown by facts, 28.6% patients achieved fibrosis improvement. More importantly, It was found that the proportions of patients with liver inflammation and fibrosis improvement were both not significantly lower than those in ETV group (53.3% vs 63.3 and 36.7% vs 43.4%). Most of patients (82.4%) with elevated baseline ALT became normal after bicyclol treatment. More importantly, as shown by the multi-variate analysis, the treatment course of bicyclol was an independent factor for liver inflammation improvement. With the HBeAg status adjusted, ALT and HBV-DNA quantity, the odds ratio (95% confidence interval) of patients with ≥48-week treatment was 5.756 (1.893,17.500) when compared with patients via < 48-week treatment. Conclusion Bicyclol can improve liver inflammation and the ALT normalization rate of CHB patients, especially when the treatment course is prolonged. This has confirmed that bicyclol could control hepatitis activity, which might be a good choice for CHB patients who refuse anti-viral treatments.http://link.springer.com/article/10.1186/s12876-019-1005-1BicyclolChronic hepatitis BHepatoprotective drugLiver biopsy |
| spellingShingle | Xiaoling Chi Huanming Xiao Meijie Shi Gaoshu Cai Yubao Xie Junmin Jiang Guangjun Tian Shuduo Wu Chaozhen Zhang Pengtao Zhao Jiezhen Chen Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience BMC Gastroenterology Bicyclol Chronic hepatitis B Hepatoprotective drug Liver biopsy |
| title | Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience |
| title_full | Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience |
| title_fullStr | Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience |
| title_full_unstemmed | Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience |
| title_short | Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience |
| title_sort | histological improvement in chronic hepatitis b patients treated with bicyclol real world experience |
| topic | Bicyclol Chronic hepatitis B Hepatoprotective drug Liver biopsy |
| url | http://link.springer.com/article/10.1186/s12876-019-1005-1 |
| work_keys_str_mv | AT xiaolingchi histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience AT huanmingxiao histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience AT meijieshi histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience AT gaoshucai histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience AT yubaoxie histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience AT junminjiang histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience AT guangjuntian histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience AT shuduowu histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience AT chaozhenzhang histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience AT pengtaozhao histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience AT jiezhenchen histologicalimprovementinchronichepatitisbpatientstreatedwithbicyclolrealworldexperience |